High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis - Wikidata - wikimedia - TriplyDB

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

http://www.wikidata.org/entity/Q28237152

about

Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease Update on inflammatory bowel disease in patients with primary sclerosing cholangitis Controversies in the management of primary sclerosing cholangitis Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver A review of the medical treatment of primary sclerosing cholangitis in the 21st century Molecular cancer prevention: Current status and future directions Primary sclerosing cholangitis: diagnosis and treatment Overlap syndromes: an emerging diagnostic and therapeutic challenge Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity?Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management Cystic fibrosis related liver disease--another black box in hepatology.Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data.Pathogenesis and clinical spectrum of primary sclerosing cholangitis.Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature.Cancer-promoting effects of microbial dysbiosis.S-adenosylmethionine in liver health, injury, and cancer.Treatment of autoimmune liver disease: current and future therapeutic options.Colitis and colorectal cancer.Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis.Current research on the treatment of primary sclerosing cholangitis.Cancer surveillance in patients with primary sclerosing cholangitis.Management of primary sclerosing cholangitis: conventions and controversies Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis Interaction of gut microbiota with bile acid metabolism and its influence on disease states.The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study Circulating CD4+CD25+ regulatory T cells in the pathobiology of ulcerative colitis and concurrent primary sclerosing cholangitis.Primary sclerosing cholangitis: diagnosis, prognosis, and management.Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases.Malignancies in Primary Sclerosing Cholangitis--A Continuing Threat Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.Recent insights in primary sclerosing cholangitis.Treatment of extraintestinal manifestations in inflammatory bowel disease.Current pharmacotherapy for cholestatic liver disease.The new prophylactic strategy for colon cancer in inflammatory bowel disease by modulating microbiota.Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I).Primary Sclerosing Cholangitis: Current and Future Management Strategies.Extraintestinal manifestations and complications in IBD.Management of the elderly patients with inflammatory bowel disease: practical considerations.Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis.

P2860

Q22241416-82E11592-5C2D-4833-8DD8-F8D131E594D1 Q24567496-3E26B04B-5005-4299-96D2-14A604FE97CA Q26765804-41FF4915-A879-4AD3-A8BE-E2277EDC20B3 Q26766699-CE2AEEED-6EDE-43EC-9277-D3F9CBC0FD44 Q26771816-95CCC63F-FFE5-4C7E-9FA5-0D4DF285822C Q26797207-90EEB6B5-2CCA-4785-9687-08F1434EF781 Q26829216-F34B8E73-ED8A-4FF4-9D13-35D2B7E8094B Q26830851-43448F29-1571-4922-A986-42C6D8CD5D35 Q26994675-C94DB201-9C2A-4097-B659-3A7CC681CCCA Q27015831-4A1EF1E7-6C4A-4D54-9AEC-B7C2134A53BA Q28655881-5E25747C-AF1E-4E24-B335-B2CEFE977EC8 Q30651444-E678AACA-2F2A-454B-A3B1-1384FF719540 Q33572623-3E727398-D22F-40C6-9C61-09D60CCDFC4E Q33958828-BDECF81B-B00A-40A9-BB66-594CF45E5143 Q34267734-73AAA41A-5242-43DA-A27E-F5D83DB74A76 Q34306534-F0C73270-EFC2-42CF-B7E6-9333D0E60B11 Q34342199-18F35B42-0C54-4728-9EAE-DFC5D549457D Q34459879-F271CA1C-4715-41E6-AF48-7B7BAD827AB3 Q34663857-774F23EE-D9C4-4320-A3CA-026FD166DD35 Q35066561-98707CD6-DD52-4726-8DEE-8C26501AAA9A Q35490961-AE0BA8FF-A2AC-4C88-A09C-7A51E028BD71 Q35962107-A5234BEC-945D-4B55-B360-9B74E5224E70 Q36101665-1E0B57CF-96D6-4BC9-A2FD-5E4BEE5B3D52 Q36204422-7D18C0EF-6190-4DB7-86D9-63CF767A2003 Q36822673-ECF37F14-3279-4DE5-A8FA-08B63333E411 Q36865862-498D3E26-06BB-474A-926A-01390E8C061C Q36955053-F3DE181C-1A27-4763-8D26-36F25DF137EF Q37018514-3E51AD84-2D00-4BA7-99FE-396A0538B5B4 Q37082378-40F4F229-8398-4389-ABB2-A5D9647C9255 Q37113520-8C06E976-7DFD-4336-851E-ED6C62A14CB9 Q37117971-A2A8F0D7-8916-44C1-9BEA-3B37A0683566 Q38019989-FD3F43FC-6496-4324-9028-B81092762E44 Q38050884-C4ECF4C2-100F-42CD-BB08-5DF742220E06 Q38055205-CB206EC9-61B7-4E3C-84DA-1BE3A57AE42A Q38068230-6962ED2D-097A-4670-B25F-79AFD8B0D7DD Q38105801-4711DA7F-36B0-46A0-A621-E5A4DE123277 Q38107484-CB0B5E31-A531-4AA4-B8E1-8F3FCE0E5FC9 Q38120146-0B75DA01-F1B5-41FF-A830-441DD47AD5BF Q38122069-13ECDFF1-F93C-4A0F-B29B-44F7537DDA02 Q38125078-AE116DFA-7DD6-41A2-A7DF-EEE0E1542114

P2860

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

http://www.wikidata.org/entity/Q28237152

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

High-dose ursodeoxycholic acid ...... primary sclerosing cholangitis

@ast

High-dose ursodeoxycholic acid ...... primary sclerosing cholangitis

@en

High-dose ursodeoxycholic acid ...... primary sclerosing cholangitis

@nl

type

label

High-dose ursodeoxycholic acid ...... primary sclerosing cholangitis

@ast

High-dose ursodeoxycholic acid ...... primary sclerosing cholangitis

@en

High-dose ursodeoxycholic acid ...... primary sclerosing cholangitis

@nl

prefLabel

High-dose ursodeoxycholic acid ...... primary sclerosing cholangitis

@ast

High-dose ursodeoxycholic acid ...... primary sclerosing cholangitis

@en

High-dose ursodeoxycholic acid ...... primary sclerosing cholangitis

@nl

P1433

Q28237152-CAB813F8-74BA-4E5A-B43C-F62ED60B55F8

P1476

Q28237152-CE20C335-6030-4F9D-9063-5268E2FFBF5C

P2093

Q28237152-11549623-C788-4BB3-82DB-C30EDC51646E

Q28237152-2050DC52-9EA2-4FBD-90B3-48CA192899D6

Q28237152-2A34B2F6-1615-41A3-8959-3A7C0FAE9BBA

Q28237152-4B9D7019-07E0-47CC-B66A-B4BC5BA64D6E

Q28237152-5008A077-5EAA-489A-912E-A5A949F616E9

Q28237152-6532D753-8AB4-4275-8208-C783416798B9

Q28237152-8F28C443-0485-406D-8E1A-B5024A7DADEC

Q28237152-944A9A0E-39FA-4F26-818A-ED3C24B2DC0C

Q28237152-A023E7B1-1AC6-4E0C-ABAB-27B3E81C53E8

Q28237152-B67AB62D-B3F2-4579-BF56-356ADB51D3AC

P2860

Q28237152-06922D64-2752-46E3-B727-D96ED7AE6AF8

Q28237152-1AC99F67-274C-4EB4-A541-EFBACAD71916

Q28237152-1BA6350D-F7DD-4363-A6DE-4435A0FC13EC

Q28237152-1C898C70-1346-4BC8-BE03-60C57E142EB3

Q28237152-2250601F-0A78-4ABF-9B48-86277A841E22

Q28237152-2C167CCD-87F4-4526-B5B9-3088C313E493

Q28237152-3CFC4359-FD92-45F8-86B5-C62070B42F22

Q28237152-469D4552-D6BE-4A0A-8286-B8929DED3EF8

Q28237152-52B54FD6-FFB8-4E82-A91E-60197FAEDD52

Q28237152-5A499548-80FE-42B8-AF29-3A8A4B535FF4

P304

Q28237152-39E18D0F-7C65-439E-B688-3EE71067EA4D

P31

Q28237152-D984CE64-A422-4DC2-95AE-74380E683FA2

P356

Q28237152-9C098283-5B1F-467E-B920-0D76EB15CAF6

P407

Q28237152-55E5FDD6-2695-4E62-A53E-BCB30C51C535

P433

Q28237152-5D834F43-EEEC-4FF5-9019-84A6AE569F56

P478

Q28237152-2A5F7F1E-1468-4F5E-97EC-0C5C424DE40E

P577

Q28237152-5ACD2DFF-C488-4BEF-BCE0-320EF3FB4130

P5875

Q28237152-A28E7825-B635-471B-8E6D-E4155DFEC7AB

P698

Q28237152-E2A36D41-8186-4D9A-825E-58D6A7147137

P921

Q28237152-3E072B18-172E-44BC-B090-ACC2DDB5B76B

Q28237152-FFE6264E-2186-4498-B84A-D09D96ACDAC6

P932

Q28237152-DCA948F5-89AB-480A-8A73-8187051537F4

P356

P1433

The American Journal of Gastroenterology

P1476

High-dose ursodeoxycholic acid ...... primary sclerosing cholangitis

@en

P2093

Alex S Befeler

http://www.w3.org/2001/XMLSchema#string

Darrell S Pardi

http://www.w3.org/2001/XMLSchema#string

Denise Harnois

http://www.w3.org/2001/XMLSchema#string

Emmanouil Sinakos

http://www.w3.org/2001/XMLSchema#string

Jan Petz

http://www.w3.org/2001/XMLSchema#string

John E Eaton

http://www.w3.org/2001/XMLSchema#string

Keith D Lindor

http://www.w3.org/2001/XMLSchema#string

Kris V Kowdley

http://www.w3.org/2001/XMLSchema#string

M Edwyn Harrison

http://www.w3.org/2001/XMLSchema#string

Marina G Silveira

http://www.w3.org/2001/XMLSchema#string

P2860

Bile acids as endogenous etiologic agents in gastrointestinal cancer

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

Conversion of 7-ketolithocholic acid to ursodeoxycholic acid by human intestinal anaerobic microorganisms: interchangeability of chenodeoxycholic acid and ursodeoxycholic acid

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Cancer risk in patients with inflammatory bowel disease.

Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.

Bile acids as carcinogens in human gastrointestinal cancers.

Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis.

Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells.

P304

1638-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJG.2011.156

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51111217

http://www.w3.org/2001/XMLSchema#string

P698

21556038

http://www.w3.org/2001/XMLSchema#string

P921

P932

3168684

http://www.w3.org/2001/XMLSchema#string